Role of Endosialin/CD248 and Cytoglobin In liver fibrosis
Al-Azhar International Medical Journal, Vol: 4, Issue: 8
2023
- 50Usage
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Usage50
- Downloads34
- Abstract Views16
Article Description
Background - Chronic liver diseases are a major global health burden. CYGB, Human IV globin is abundantly expressed in Hepatic Stellate Cell(HSCs) between hepatocytes. CYGB can bind oxygen and nitric oxide and is said to protect HSCs from reactive oxygen species(ROS).Aim - to estimate role of CD248 and Cygb in process of liver fibrosis.Patients and Methods - This study was conducted on forty-four Egyptian patients with hepatic stenosis detected by ultrasound, and forty healthy volunteers as control group.Results - Our results showed statistical significant (p-value < 0.001) increased CD248 in patients group (189.03 ± 66.6) when compared with control group (138.7 ± 36.5), decreased Cygb in patients group (1.62 ± 0.35) when compared with control group (1.93 ± 0.26)Conclusion - Our study identified Cygb and CD248 as a novel therapeutic-targets in liver-fibrosis.
Bibliographic Details
Al-Azhar University
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know